WINTER PARK, Fla., Mar. 12 -- LaserSight Inc. has filed a PMA Supplement with the US Food and Drug Administration requesting approval to use its LaserScan LSX excimer laser system to perform LASIK treatment of mixed astigmatism with the astigmatic component in the range of + 0.5 to + 6.0 diopters. LaserSight now has five PMA Supplements under active consideration by the FDA. "We are continuing to file PMA Supplements that, when approved, will allow refractive surgeons using our LaserScan LSX system to treat a broad range of refractive error using the same advanced state-of-the-art precision beam microspot scanning technology the company has provided to its international customers for over two years," said Michael R. Farris, president and CEO of LaserSight. "Since May 1998, LaserSight's international customers have been using their LSX systems to treat the entire range of refractive errors including myopia, hyperopia, astigmatism and mixed astigmatism."